Anidulafungin Intravenous Infusion for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Restricted antifungal
- Its present place in therapy is as an alternative to caspofungin in NON-neutropenic patients on the direct recommendation of microbiology or infectious diseases
Infusion-related adverse events have been reported, including rash, urticaria, flushing, pruritus, dyspnoea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of infusion does not exceed 1.1 mg/min
For Y-site compatibility see below

Anidulafungin 100mg

Sodium chloride 0.9% or Glucose 5%

Intermittent intravenous infusion

Add 100mg reconstituted vial (30ml) to 100ml infusion fluid
Add 200mg reconstituted vials (60ml) to 200ml infusion fluid (withdraw 50ml from 250ml bag)
Administer at a rate of 1.4ml per minute
i.e. 100mg dose (in 130ml) over 90 minutes
i.e. 200mg dose (in 260ml) over 180 minutes

Loading with 200mg (DAY ONE ONLY), then give 100mg every twenty four hours thereafter

Renal or hepatic impairment

No dosage adjustment for renal insufficiency including those on renal replacement therapy
No dosage adjustment for any degree of hepatic impairment (but see under monitoring below)

Isolated cases of significant hepatic dysfunction, hepatitis or worsening hepatic failure have been reported. Patients with hepatic impairment should be monitored for worsening hepatic function while on anidulafungin, and evaluated for risk benefit of continuing anidulafungin therapy

Infusion related reactions have been reported.
It is important NOT to exceed the recommended rate of administration to minimise the possibility of such reactions

Anidulafungin TEVA SPC- June 2022

Antifungal

BNF